| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H16N2O |
| Molar mass | 192.262 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Pozanicline (INN,[1] codenamedABT-089) is a drug developed byAbbott, that hasnootropic andneuroprotective effects.[2][3][4] Animal studies suggested it useful for the treatment ofADHD[5] and subsequent human trials have shown ABT-089 to be effective for this application.[6] It binds with high affinitysubtype-selective to theα4β2nicotinic acetylcholine receptors and haspartial agonism to theα6β2 subtype,[7][8] but not theα7 andα3β4 subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class.[9][10]
Pozanicline is synthesized from 2-methyl-3-hydroxypyridine and Boc-L-Prolinol through a dehydration reaction followed by deprotection of the nitrogen atom of prolinol[11]